针灸在乳腺癌化疗不良反应的应用及机制研究
Breast cancer patients receiving chemotherapy usually have a series of adverse reactionswhich seriously affects the survival quality of patients and also brings challenges to clinical treatment. Acupunctureas a safe and easily accepted treatment modalityshows potential in improving adverse reactions after chemotherapy with its unique efficacy. Although some progress has been made in the study of acupuncture for the treatment of post-chemotherapy adverse effects in breast cancer patientsthe current study focuses on a single research leveland there is a lack of systematic integration and sorting of related studiesand the related mechanism studies are mostly preliminary explorationswhich haven't formed a complete theoretical system. In additionacupuncture hasn't formed a widely recognized standardized guideline for the treatment of this areawhich to a certain extent restricts the standardization of the application in the clinical treatment. The application of acupuncture has been limited to some extent by standardization in clinical treatment. By systematically integrating the applied studies and mechanisms of acupuncture action in the treatment of adverse reactions after breast cancer chemotherapy in SCI source journalsthis study concludes that a rich chain of evidence has been formed for the intervention value of acupuncture in the adverse reactions to breast cancer chemotherapy. Acupuncture and moxibustion can significantly improve the digestive system symptomsperipheral neuropathybone marrow depressioncancer-related fatigue and other core symptoms after chemotherapy by regulating the level of inflammatory factorsregulating the nervous system and related signaling pathwaysand play a therapeutic role.This article provides future clinical applications of acupuncture in the treatment of adverse effects of chemotherapy in breast cancer as well as in-depth studies of the mechanism of action.
任园园、刘胜
330004江西省南昌市 江西中医药大学200032上海市 上海中医药大学附属龙华医院
中医学临床医学肿瘤学基础医学
乳腺癌针灸化疗不良反应临床应用
任园园,刘胜.针灸在乳腺癌化疗不良反应的应用及机制研究[EB/OL].(2025-05-08)[2025-07-25].https://chinaxiv.org/abs/202505.00100.点此复制
评论